Sharemaestro Newsreel

Eton Now Expects 2026 Revenue to Exceed $145M After Q2

Eton Pharmaceuticals reported strong Q2 2026 financial results, with net revenue surging 99% year-over-year to $37.6 million. Driven by the successful relaunch of HEMANGEOL and growth across its rare disease portfolio, the company has raised its full-year 2026 revenue guidance to exceed $145 million …

Centrum Reframes Healthy Aging as a Proactive Practice for Adults 35 and Beyond

With the introduction of Centrum Age Defy alongside the trusted Centrum Silver portfolio, Centrum is helping redefine healthy aging as a lifelong journey, not a destination. Key Takeaways Centrum, the #1 doctor- and pharmacist-recommended multivitamin brand, is helping redefine healthy aging as a proactive, …

Michael Burry Sends Fresh AI Warning on Nebius, Micron and Oracle

This article first appeared on GuruFocus. Michael Burry (Trades, Portfolio) has increased bearish positions tied to artificial intelligence and semiconductor stocks, while adding to selected long holdings, according to a Wednesday Substack post. Warning! GuruFocus has detected 3 Warning Signs with MU. Is MU …

Indivior Pharmaceuticals, Inc. (INDV) Options Chain

This article provides the options chain for Indivior Pharmaceuticals, Inc. (INDV), listing both call and put options with their respective strike prices, last trade dates, prices, and other relevant data. It includes current stock performance and related pharmaceutical tickers.

Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover?

Prestige Consumer Healthcare (NYSE:PBH) closed two acquisitions within three weeks this summer, adding roughly $240 million in annualized revenue to a portfolio anchored by Dramamine and Compound W. The first quarter fiscal 2027 earnings call, held August 6, showed a company beating its own …

Viatris (VTRS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, August 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS CEO - Scott SmithInterim CFO - Paul CampbellChief R&D Officer - Philippe MartinChief Commercial Officer - Corinne Le GoffHead of Capital Markets - Bill Szablewski TAKEAWAYS Revenue -- …

Can Asceniv Help ADMA Stock Combat IG Market Challenges?

ADMA Biologics ADMA is a U.S.-based commercial-stage biopharmaceutical company focused on developing, manufacturing and marketing specialty biologics for immunodeficient patients and individuals at risk of certain infectious diseases. The company currently markets three FDA-approved plasma-derived biologics: Asceniv (immune globulin intravenous – slra 10% liquid) …

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia Corporation LQDA reported second-quarter 2026 earnings per share (EPS) of 74 cents, which topped the Zacks Consensus Estimate of 70 cents. In the year-ago quarter, the company reported a loss per share of 49 cents. Total revenues surged to $171.7 million from $8.8 …

Amylyx (AMLX) Q2 2026 Earnings Call Transcript

Liquidia CEO Roger Jeffs Says Demand For Inhaled Lung Disease Drug Is Growing Amid Q2 Revenue Beat

Liquidia reported a strong second quarter, with total revenue of $171.7 million, exceeding Wall Street estimates, largely driven by sales of its inhaled lung disease drug, Yutrepia. Since its launch in June 2025, Yutrepia has received approximately 5,900 unique patient prescriptions and contributed significantly …

Phibro Animal Health (PAHC) Stock Looks Undervalued On Earnings Yet Mixed Elsewhere

United Therapeutics (UTHR) Stock Looks Undervalued Despite Fresh NDA Filings

Dr. Reddy’s Laboratories (RDY) CEO API & Services Deepak Sapra resigns effective November 12, 2026

Dr. Reddy’s Laboratories announced that Deepak Sapra, CEO of API & Services and a Senior Management Personnel, has resigned to pursue outside opportunities. His resignation is effective November 12, 2026, and he will remain with the company until then to ensure a smooth transition …

Liquidia: YUTREPIA Reaches 5,000+ Patients As Inhaled Prostacyclin Market Expands Nearly 40%

Liquidia's YUTREPIA has reached over 5,000 patients and generated $170.4 million in Q2 net product sales, contributing to a nearly 40% expansion of the inhaled prostacyclin market since its launch. The company has seen four consecutive quarters of increasing profitability and is pursuing a …

LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path

Liquidia Corporation's Q2 2026 earnings call emphasized the growth of YUTREPIA, aiming for over $1 billion in net revenue by 2027 through commercial expansion and increased adoption. The company reported strong Q2 financial results, with EPS and revenues exceeding consensus estimates, and plans to …

Takeda Pharmaceutical (TAK) executive reports sale of 20,363 ADS at $17.55

Shannon Elaine Mary, President of Global Supply & Quality at Takeda Pharmaceutical Co. Ltd. (TAK), sold 20,363 American Depositary Shares (ADS) at a price of $17.55 per ADS on August 11, 2026. This transaction was an open market or private sale, and after the …

Takeda Pharmaceutical (NYSE:TAK) Insider Andrew Stewart Plump Sells 165,393 Shares of Stock

Andrew Stewart Plump, an insider at Takeda Pharmaceutical (NYSE:TAK), sold 165,393 shares of the company's stock for approximately $2.83 million. This sale was conducted to cover tax obligations from vested equity awards, reducing his stake by 17.75%. Despite mixed analyst ratings, with a consensus …

Takeda (TAK) President IBU sells 31,083 ADSs in tax-related transaction

Giles Richard Platford, President, IBU of Takeda Pharmaceutical Co Ltd (TAK), sold 31,083 American Depositary Shares (ADSs) on August 10, 2026, at a weighted average price of $17.10 per share. This transaction was a mandatory sale to cover taxes associated with the vesting of …

FTC lawsuit alleges Hims & Hers charged consumers for unwanted prescriptions

The Federal Trade Commission, alongside the State of California and Utah Division of Consumer Protection, has filed a lawsuit against Hims & Hers Health Inc. The lawsuit alleges that Hims & Hers misled consumers by charging them for prescription medication subscriptions they never agreed …

Cardiol Therapeutics GAAP EPS of -C$0.05

* Cardiol Therapeutics press release [https://seekingalpha.com/filing/309942772] (CRDL:CA [https://seekingalpha.com/symbol/CRDL:CA]): Q2 GAAP EPS of -C$0.05. MORE ON CARDIOL THERAPEUTICS * Historical earnings data for Cardiol Therapeutics [https://seekingalpha.com/symbol/CRDL:CA/earnings] * Financial information for Cardiol Therapeutics [https://seekingalpha.com/symbol/CRDL:CA/income-statement]

Eton Pharmaceuticals earnings ahead: Profitability in focus

Eton Pharmaceuticals is expected to report second-quarter earnings with analysts forecasting $0.15 per share on $26.88 million in revenue, a significant improvement from the prior quarter. Investors will be closely watching for continued commercial execution, especially from recent product launches, and evidence that the …

Caring Brands, Inc. Q2 2026: Revenue $0 EPS $(0.10) — 10-Q Summary

Caring Brands, Inc. (CABR) reported zero revenue for Q2 2026, a significant drop from the previous year, and a wider net loss of $(935,019) due to continued investments in product development and public-company operations. The company's diluted EPS was $(0.10), worsening from $(0.05) in …

Liquidia (NASDAQ:LQDA) Price Target Raised to $92.00

Bank of America has raised its price target for Liquidia (NASDAQ:LQDA) to $92.00 from $79.00, maintaining a "neutral" rating, indicating a potential 16.77% upside. This comes despite Liquidia's recent quarterly earnings showing revenue growth of 1,842.1% year-over-year to $171.68 million and net income of …

Zoetis (ZTS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Steve FrankChief Executive Officer - Kristin PeckChief Financial Officer - Wetteny Joseph TAKEAWAYS Revenue -- $2.5 billion, representing a flat result on …

Equities Analysts Issue Forecasts for ETON FY2027 Earnings

Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research

Zacks Research upgraded Emergent BioSolutions (NYSE:EBS) to a "Hold" rating. Despite beating Q2 earnings estimates, the company faces analyst forecasts for a full-year loss, increased competition, and pricing pressure, leading to a significant impairment charge against its NARCAN franchise. The stock currently has a …

Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating

Deutsche Bank has adjusted its price target for Neurocrine Biosciences (NBIX) to $165, down from $190, while maintaining a Hold rating on the stock. This adjustment comes amidst recent news including positive Phase 4 study results for Ingrezza capsules and the initiation of a …

Renaissance Technologies LLC Lowers Stake in Evolus, Inc. $EOLS

Renaissance Technologies LLC significantly reduced its stake in Evolus, Inc. (NASDAQ:EOLS) by 57.6% in the first quarter, selling 460,875 shares and retaining 339,025 shares valued at $1.39 million. Despite this, institutional investors collectively own about 90.69% of Evolus, and several other funds have recently …

Haleon plc (NYSE: HLN) prices $2B multi‑tranche bond to target 2027 notes

Haleon plc announced its subsidiary, Haleon Capital LLC, has priced a $2 billion SEC-registered bond offering across three tranches maturing in 2029, 2031, and 2036, with coupons ranging from 4.625% to 5.375%. The company intends to use the net proceeds, along with cash on …

Haleon prices $2B bond, one of UK health's largest debt raises

Haleon, the UK consumer health group, has priced a $2 billion three-tranche bond offering through its subsidiary Haleon US Capital LLC. The offering aims to repurchase outstanding notes due in March 2027 and refinance debt, with the remaining proceeds for general corporate purposes. This …

Haleon prices $2bn bond offering across three tranches By Investing.com

Haleon US Capital LLC, a wholly-owned subsidiary of Haleon plc, has priced a $2 billion bond offering across three tranches, maturing in 2029, 2031, and 2036 with varying coupon rates. The offering is expected to settle on August 21, 2026, and the proceeds, guaranteed …

The Top 5 Analyst Questions From Zoetis’s Q2 Earnings Call

United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play

Talphera signals ~$200,000 annual U.S. CRRT procedures in 2027 market sizing as NEPHRO CRRT reaches 75% enrollment

Earnings Call Insights: Talphera (TLPH) Q2 2026 MANAGEMENT VIEW * “With all of our final clinical sites now activated, we have reached 75% enrollment in the NEPHRO CRRT study,” said CEO Vincent Angotti, adding, “We remain on track to complete enrollment in the NEPHRO …

BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain

Burry adds to AI shorts, says ‘Nebius is what the top of a boom looks like’

Astrid Stawiarz Michael Burry disclosed updated stock positions on Wednesday, adding to his short bets on Nebius (NBIS [https://seekingalpha.com/symbol/NBIS]), Micron (MU [https://seekingalpha.com/symbol/MU]), Oracle (ORCL [https://seekingalpha.com/symbol/ORCL]), and the iShares Semiconductor ETF (SOXX [https://seekingalpha.com/symbol/SOXX]), while increasing his long positions in Mercado Libre (MELI [https://seekingalpha.com/symbol/MELI]) and Zoetis …